11th Annual (Virtual) World Bispecific Summit 22-24 September, 2020

The Process of CDMO Selection for Bispecific Antibody Development: Matching Capabilities to Need

Steven Chamow, Ph.D. Chamow & Associates, Inc. San Mateo, CA USA



Overview

• The Challenge

- Client company/project
- Target product profile
- · How to use a consultant in this process
- The Match
 - Considerations for candidate CDMOs
- Scope of Work
 - Development
 - GMP production
 - Timing of pre-IND meeting, IND
- Summary



The Challenge



The Client

- Small, venture-funded Bay Area biotechnology company
- Internal capabilities
 - POC research laboratory
 - No CMC development infrastructure
- Monoclonal antibody discovery platform
- Oncology focus

The Project

- Client company sought to develop pre-clinical mAb
 - Product
 - Humanized IgG1, not a bispecific
 - Hired external consulting group to execute CMC
 - Identify, evaluate and select and manage CDMO
 - Develop pre-IND strategy
 - Write CMC module of IND
 - Starting point
 - In silico amino acid sequence
 - Target product profile



Target Product Profile (TPP)

- "Needs checklist"
- Defines product characteristics
 - Product description
 - Indications and usage
 - Dosage and administration
 - Dosage forms and strengths
 - How supplied and handling
- Provided client with a roadmap to guide product development
 - Anticipated dose and clinical indications \rightarrow amount needed for clinical studies \rightarrow scale of production
 - Route of administration \rightarrow type of formulation




Preclinical TPP

- Clinical indication oncology Scale of production – 1000 or 2000 L
- Route of administration infusion 10 mg/mL liquid solution 2-8 deg C storage

Characteristic	Detail				
Product Information					
Product name					
Molecular description	Humanized IgG1/k				
Biological activity	-				
Proposed mechanism of					
action					
Structural requirements					
DS Stability	24 mo -20 deg C				
Dosage Form	Buffered liquid solution				
DP Stability	36 mo 2-8 deg C				
Route of Administration	Intravenous				
Dosage Strength	10 mg/kg				
Pharmacokinetics					
Container and Closure	Glass vial				
System					
Production DS					
CDMO					
Cell line	СНО				
Target productivity at	3 g/L				
harvest					
Production scale (L)	2000L				
Estimated overall yield	80%				
(%)					
Batch size (kg)	4.8 kg				
Production DP					
CDMO					
Estimated yield (%)					
Batch size (# vials)					
Forecast (projected					
demand for Ph3 clinical					
trials, launch and first 5					
years on market)					
Labeling and Clinical Packaging					
Vendor					



Use of CMC consultants to select and manage CDMOs





The Match




We evaluated CDMOs with different capabilities and expertise

- Expertise varies
 - Enzymes
 - Cytokines
 - Growth factors
 - Monoclonal antibodies
 - Bispecifics
 - Fusion proteins (Fc, albumin)
 - ADCs
- Capabilities vary (one-stop shop or not)



Project stages and timeline





Factors in Matching Client to CDMO

- Phase of development
 - Phase 1/IND vs. Phase 3/commercial
- Priorities
 - Quality
 - Cost
 - Time
 - Considered that cost and time are trade-offs
- Cell line
 - Productivity
 - Terms of access
 - Proprietary vs. non-proprietary



Factors (cont'd.)

- One-stop shop or different CDMOs
 - Cell line development
 - Not all CDMOs are equally good at making cell lines
 - Wanted a CDMO with proprietary technology
 - Process development
 - Formulation development
 - This formulation was straightforward
 - Analytical methods/Stability
 - MCB-production/characterization
 - cGMP
 - DS
 - DP





Scope of Work



The starting point... Synthesizing cDNA from an amino acid sequence

mAb y1 Heavy Chain

Amino Acid Sequence

MAVLGLLFCLVTFPSCVLSQVQLKESGPGLVAPSQSLSITCTVSGFSLTDYGVRWIRQPPGKGLEWLGVIWGGGSTYYNSALKSRLSISKDNSKSQVFLKMNSLQTDDTAMYYCAKEKRR GYYYAMDYWGQGTSVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTVICNVNHKPSNTKVDKKAEP KSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTIS KAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGKTS

cDNA Sequence



...to the goal Producing bulk drug substance and filled and labelled drug product









Scope of Work Development

- Cell Line
 - cDNA synthesis and plasmid construction
 - Cell line
 - RCB
 - MCB
- Process
 - Upstream
 - Downstream
 - Formulation
- Analytical
 - Compendial
 - Product-specific
 - Platform methods
 - Potency





Scope of Work (cont'd.)

Scale Up and Clinical Production

- Tox production
 - Reference material
 - Preliminary DP stability
- Characterization of reference material
- GMP production of DS
 - Viral clearance study
 - ICH Stability
- GMP production of DP
 - ICH Stability
- Clinical labelling, packaging and distribution






Cell line and process development



Elements of the process





First consideration: Cell line/expression system

Type of cell line	Expected productivity	Timeline*	Cell line stability	Cost components		
				Fee for service	Milestone payments	Royalty
Proprietary (requires license)	3-7 g/L, may require proprietary media	3-6 mo aa sequence to RCB	60-generation confirmation may not be critical path task	Yes	Yes	Few
Non-proprietary (public domain)	1-3 g/L, generally with commercial media	6-9 mo, aa sequence to RCB	60-generation confirmation of stability is critical path task	Yes	No	No

*Includes 1 mo for DNA codon optimization, synthesis + 1 mo for plasmid construction




Special considerations for bispecifics

- Vector design
 - Single vs. multiple plasmid system
 - Assembly of the oligomer may vary with differential expression of monomer chains
 - Chain ratio may need to be optimized
 - Multiple plasmids provide greatest flexibility
- Structure and stability
 - Implications for use of a platform process
 - Stability at extremes of pH
 - Acid stability required for capture on Protein A, low pH hold for virus inactivation
 - Purification complexities
 - Product variants as impurities
 - Removal of variants will define final polishing chromatography





We went with Chinese hamster ovary cells/proprietary expression system





Productivity of cell culture process

• Titer (mg/L) is determined by accumulated cell mass x cell specific productivity

Titer = qp•∫xdt


Where qp = cell specific productivity ∫xdt = cell mass


- A good process...
 - Starts with a highly productive cell line
 - Produces high accumulated cell mass
 - Time in production phase with high cell viability
 - Timing and composition of feeds
 - Provide just-in-time nutrients and minimize waste products
 - Rate of agitation, oxygenation (sparging)



Second consideration: Cell culture process design


- Fed-batch
- Perfusion







Process development runs—Product titer





GMP Production




Scale up

- Confirmation runs at 2 L bench scale
 - Performed with RCB
 - Confirmed performance of complete process
- Tox production
 - Performed with MCB
 - Pilot scale (100 L R&D)
 - Process reflects GMP process
 - Generates reference material
 - Preliminary DS, DP stability to support GMP stability
- GMP production
 - Performed with MCB
 - 2000 L
 - Samples taken for
 - Virus clearance study
 - DS, DP stability
 - Qualified assays




Tox vs. bioreactor confirmation runs – VCD






Tox vs. bioreactor confirmation runs - Viability






Tox vs. bioreactor confirmation runs – Titer






Summary of process - mAb bulk drug substance (DS)





Summary of process - mAb drug product (DP)





Liquid DP filled into glass vials



Formulation development and drug product stability studies

- Developed a stable formulation for storage of DS (-20°C)
- Developed a stable formulation for DP (2-8°C)
 - Evaluated
 - pH
 - Excipients
 - Formulation selected based on 3-month stability data
 - Goals
 - Liquid DP formulation (10 mg/mL) for intravenous administration
 - Stable DP product for >24 months at 2-8°C storage
 - DP is compatible with container/closure system and in-use compatibility (if DP to be diluted in IV bag)
- Key stability-indicating assays










When did we time interactions with FDA?





Summary

- If you are a scientist at a company wishing to develop a new biologic for clinical testing, plan on outsourcing manufacturing to a competent CDMO
- A CDMO can design a production process and can provide high quality product to meet regulatory requirements in sufficient quantity
- CDMO's have particular expertise, and capabilities should be evaluated carefully
- Plan on 1-2 years to develop a cell line and process and manufacture tox and clinical product
- Plan your interactions with FDA around the uniqueness of your product
- You may want to seek a CMC consultant to assist in this effort



Questions

Steven Chamow, PhD

steve@chamowassociates.com (650) 274-3753

www.chamowassociates.com

